Buminate Human Albumin

Buminate 20% [albumin (human)], usp, 20% solution
buminate 20% is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.
Do not use if turbid. Do not begin administration more than 4 hours after the container has been entered.
Do not use sterile water for injection as a diluent. There exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of sterile water for injection as a diluent for buminate 20%. Acceptable diluents include 0.9% sodium chloride or 5% dextrose in water.
Buminate 20% is made from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the creutzfeldt–jakob disease (cjd) agent.
The stoppers used in buminate 20% contain natural rubber latex.
Buminate 20% must be administered intravenously at a rate not to exceed 1mlmin to patients with normal blood volume, due to the risk of developing circulatory overload and pulmonary edema.
When buminate 20% is infused, a rise in blood pressure necessitates careful observation to detect and treat severed blood vessels that may not have bled at a lower blood pressure.
Adverse reactions to buminate 20% are extremely rare, although nausea, fever, chills or urticaria may occasionally occur. Such symptoms usually disappear when the infusion is slowed or stopped for a short period of time.